Page last updated: 2024-09-03

imatinib mesylate and Adenoma, Prostatic

imatinib mesylate has been researched along with Adenoma, Prostatic in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Crawford, SE; Filipovich, Y; Franco, OE; Hayward, SW; Ishii, K; Katayama, N; Ohishi, K; Sasaki, T; Sugimura, Y; Takahashi, N	1
Hamakawa, T; Hayashi, Y; Imura, M; Kohri, K; Kojima, Y; Kubota, Y; Sasaki, S; Yasui, T	1

Other Studies

2 other study(ies) available for imatinib mesylate and Adenoma, Prostatic

Article	Year
Tyrosine kinase inhibitor therapy prescribed for non-urologic diseases can modify PSA titers in urology patients. The Prostate, 2019, Volume: 79, Issue:3 Topics: Aged; Cell Line, Tumor; Cell Proliferation; Humans; Imatinib Mesylate; Kallikreins; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Prostate-Specific Antigen; Prostatic Hyperplasia; Prostatic Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Receptors, Androgen; RNA, Messenger	2019
Regulation of cell proliferation through a KIT-mediated mechanism in benign prostatic hyperplasia. The Prostate, 2012, Oct-01, Volume: 72, Issue:14 Topics: Aged; Benzamides; Blotting, Western; Cell Growth Processes; Cell Line; Gene Expression Regulation; Humans; Imatinib Mesylate; Immunohistochemistry; Janus Kinase 2; Male; Piperazines; Prostatic Hyperplasia; Proto-Oncogene Proteins c-kit; Pyrimidines; Real-Time Polymerase Chain Reaction; RNA, Messenger; STAT1 Transcription Factor; Stem Cell Factor; Stromal Cells	2012

Article

Year

Tyrosine kinase inhibitor therapy prescribed for non-urologic diseases can modify PSA titers in urology patients.

The Prostate, 2019, Volume: 79, Issue:3

Topics: Aged; Cell Line, Tumor; Cell Proliferation; Humans; Imatinib Mesylate; Kallikreins; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Prostate-Specific Antigen; Prostatic Hyperplasia; Prostatic Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Receptors, Androgen; RNA, Messenger

2019

Regulation of cell proliferation through a KIT-mediated mechanism in benign prostatic hyperplasia.

The Prostate, 2012, Oct-01, Volume: 72, Issue:14

Topics: Aged; Benzamides; Blotting, Western; Cell Growth Processes; Cell Line; Gene Expression Regulation; Humans; Imatinib Mesylate; Immunohistochemistry; Janus Kinase 2; Male; Piperazines; Prostatic Hyperplasia; Proto-Oncogene Proteins c-kit; Pyrimidines; Real-Time Polymerase Chain Reaction; RNA, Messenger; STAT1 Transcription Factor; Stem Cell Factor; Stromal Cells

2012